Chondroitin sulfate proteoglycan (CSPG), a matrix protein that occurs naturally in the central nervous system (CNS), is considered to be a major inhibitor of axonal regeneration and is known to participate in activation of the inflammatory response. The degradation of CSPG by a specific enzyme, chondroitinase ABC, promotes repair. We postulated that a disaccharidic degradation product of this glycoprotein (CSPG-DS), generated following such degradation, participates in the modulation of the inflammatory responses and can, therefore, promote recovery in immuneinduced neuropathologies of the CNS, such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU). In these pathologies, the dramatic increase in T cells infiltrating the CNS is far in excess of the numbers needed for regular maintenance. Here, we show that CSPG-DS markedly alleviated the clinical symptoms of EAE and protected against the neuronal loss in EAU. The last effect was associated with a reduction in the numbers of infiltrating T cells and marked microglia activation. This is further supported by our in vitro results indicating that CSPG-DS attenuated T cell motility and decreased secretion of the cytokines interferon-γ and tumor necrosis factor-α. Mechanistically, these effects are associated with an increase in SOCS-3 levels and a decrease in NF-κB. Our results point to a potential therapeutic modality, in which a compound derived from an endogenous CNS-resident molecule, known for its destructive role in CNS recovery, might be helpful in overcoming inflammationinduced neurodegenerative conditions. Key words: encephalomyelitis • experimental autoimmune uveitis • immunosuppression hondroitin sulfate proteoglycan (CSPG) is a matrix component that is expressed naturally in the central nervous system (CNS); it is up-regulated after CNS injury (1-3) and during the course of chronic neurodegenerative disorders such as multiple sclerosis (MS) (4), Alzheimer's disease (5, 6), and glaucoma (7, 8) . CSPG is considered to be a major factor C Page 1 of 24 (page number not for citation purposes) inhibiting regeneration in the CNS (9-11) due to its growth inhibitory effect on neurons (11) (12) (13) and its association with the activation of immune components (14) . A number of studies showed that degradation of CSPG in vivo, using the enzyme chondroitinase ABC (ChABC), promote recovery (11, 12, 15, 16) . Our group has previously demonstrated that a disaccharidic (DS) product of CSPG degradation, 6-sulfated disaccharide, CSPG-DS, induces axonal growth and activates microglia to adopt a neuroprotective phenotype (17). We proposed that CSPG-DS might also contribute to the regulation of the inflammatory response in the CNS and might have a potential modulating effect on inflammation-associated neurodegenerative conditions in the CNS.
inhibiting regeneration in the CNS (9-11) due to its growth inhibitory effect on neurons (11) (12) (13) and its association with the activation of immune components (14) . A number of studies showed that degradation of CSPG in vivo, using the enzyme chondroitinase ABC (ChABC), promote recovery (11, 12, 15, 16) . Our group has previously demonstrated that a disaccharidic (DS) product of CSPG degradation, 6-sulfated disaccharide, CSPG-DS, induces axonal growth and activates microglia to adopt a neuroprotective phenotype (17) . We proposed that CSPG-DS might also contribute to the regulation of the inflammatory response in the CNS and might have a potential modulating effect on inflammation-associated neurodegenerative conditions in the CNS.
The primary cause of inflammation-associated neurodegenerative conditions is not fully understood. However, it is known that excessive levels of activated T cells, and in many cases also of nitric oxide (NO) and TNF-α secreting microglia/macrophages, are found in the affected CNS (18) (19) (20) (21) . Often, these pathologies are treated by immunosuppressive, steroidal drugs such as methylprednisolone (MP) (22) (23) (24) . Although such treatments result in the suppression of the inflammatory response, steroids may cause further damage to the neural tissue manifested by either neuronal loss or impairment of remyelination (25) (26) (27) . This destructive phenomenon can be attributed, at least in part, to the fact that eliminating the immune response altogether, rather than its modulation, prevents the potential benefit within a balanced immune response.
The aim of this study was to test the hypothesis that CSPG-DS (generated following ex vivo degradation of CSPG using ChABC) has the capacity to modulate inflammatory responses associated with neurodegenerative diseases in which overwhelming T cell activity is a key factor. We therefore examined the ability of CSPG-DS to promote recovery and neuronal survival in the experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU) models, and tested its effects on components of the immune system such as T cells and microglia/macrophages.
MATERIALS AND METHODS

Reagents
Fetal calf serum (FCS), horse serum, fetal bovine serum (FBS), HEPES buffer, antibiotics, sodium pyruvate, and DMEM were all purchased from Beit-Ha-Emek, (Kibbutz Beit Ha-Emek, Israel). Phosphatase inhibitor cocktail, phosphate-buffered saline (PBS), β-mercaptoethanol, RPMI-1640, and bovine serum albumin (BSA) were from Sigma-Aldrich (St. Louis, MO). Other reagents used were CSPG-DS: α-ΔUA-[1⇒3]-GalNAc-6S (ΔUA=4-deoxy-L-threo-hex-4-enopyranosyluronic acid; GalNAc = N-acetyl-D-galactosamine; 6S=6-sulfate) (C-4170; Sigma, Steinheim, Germany); fibronectin (FN; Chemicon, Temecula, CA); recombinant human stromalcell-derived factor-1α (SDF-1α) ( 
Animals
C57Bl/6J and Balb/c mice and Lewis rats were supplied by the Weizmann Institute's Animal Breeding Center. All animals were handled according to the National Institutes of Health Guidelines for the Management of Laboratory Animals. They were housed in a light-and temperature-controlled room and were matched for age in each experiment.
Induction of EAE
Mice were immunized subcutaneously (sc) at one site in the flank with 200 µl of emulsion consisting of MOG 1-22 (300 µg per mouse) emulsified in complete Freund's adjuvant (CFA), supplemented with 500 µg of Mycobacterium tuberculosis (Difco, Detroit, MI). CSPG-DS (5 µg per injection) was administered intravenously (iv). Clinical symptoms of EAE were examined and scored daily, as follows: 0, no clinical disease; 0.5, piloerection; 1, tail weakness; 1.5, tail paralysis; 2, hind limb weakness; 3, hind limb paralysis; 3.5, forelimb weakness; 4, forelimb paralysis; 5, moribund state or death.
Induction of EAU
To induce EAU, Lewis rats were immunized with the R16 peptide (30 µg) emulsified in CFA containing 2.5 mg/ml M. tuberculosis. A total volume of 100 µl was injected subcutaneously into each rat at the root of the tail. The rats were then divided into three groups. On days 3, 6, 9, 12, and 17 after immunization, the rats in the first group were injected intraperitoneally with CSPG-DS (15 µg/rat), and rats in the second group were injected intraperitoneally with methylprednisolone (MP; Solu-Medrol, 125 mg/ml; Pharmacia and Upjohn, Puurs, Belgium). Rats in third group were injected with PBS. RGC survival was assessed as described before (28) .
Anatomical assessment of retinal damage
The hydrophilic neurotracer dye dextran tetramethylrhodamine (Rhodamine Dextran) (Molecular Probes, Oregon) was applied directly into the intraorbital portion of the optic nerve. Only axons that survive and remain functional, and whose cell bodies are still viable, can take up the dye and demonstrate labeled RGCs. Twenty-four hours after dye application, the rats were killed and their retinas were excised, whole-mounted and preserved in 4% paraformaldehyde. RGCs were counted under a Zeiss fluorescent microscope (×800 magnification). Four fields from each retina were counted, (all with the same diameter (0.076 mm 2 ) and located at the same distance from the optic disc). Eyes from untreated rats were used as a control. RGCs were counted by an observer who was blinded to the identity of the retinas.
Immunocytochemistry
Cryosections excised rat eyes were picked up onto gelatin-coated glass slides and frozen pending preparation for fluorescence staining. The sections were fixed in ethanol for 10 min at room temperature, washed twice with double-distilled water, and incubated for 3 min in PBS containing 0.05% Tween-20. Sections were incubated for 1 h at room temperature with mouse anti-rat monoclonal antibodies to MHC-II (clone number: HIS28; IQ Products, Groningen, The Netherlands), griffonia simplicifolia isolectin (fluorescent lectin (FITC-IB4)), or TCR (Acris Antibodies, GmbH) diluted in PBS containing 3% fetal calf serum and 2% bovine serum Page 3 of 24 (page number not for citation purposes) albumin. The sections were then washed three times with PBS containing 0.05% Tween-20, and incubated with Cy3-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature. Control sections (not treated with primary antibody) were used to distinguish specific staining from staining of nonspecific antibodies or autofluorescent components. Sections were viewed with a fluorescence microscope (Carl Zeiss Meditech; Oberkochen, Germany).
Assay for delayed-type hypersensitivity
Groups of female inbred Balb/c mice were sensitized with 2% oxazalone (100 µl) dissolved in acetone/olive oil [4:1 (vol/vol)] and applied topically to the shaved abdominal skin. CSPG-DS were injected intravenously at the indicated concentrations. A delayed-type hypersensitivity (DTH) response was elicited 5 days later by challenge with 0.5% oxazalone in acetone/olive oil (10 µl applied topically to each side of one ear). Ear thickness was measured with an engineer's micrometer (Mitutoyo, Elk Grove Village, IL) immediately before, and 24 h after antigen challenge.
Human T cells
T cells from the peripheral blood of healthy donors were isolated by negative selection using a RosetteSep TM antibody cocktail, as described previously (29) .
T cell adhesion assays
Adhesion of human T cells to FN was assayed as described (30) . Cells were preincubated with CSPG-DS at the indicated concentration for 2 h before their exposure to SDF-1α.
T cell chemotaxis
Migration of purified human T cells was measured with a transwell apparatus, as described previously (30) . The filters separating the upper and lower chambers were pretreated with FN (20 µg/ml) for 1 h at 37°C. The 51 [Cr]-labeled T cells were preincubated for 2 h with CSPG-DS at the indicated concentrations and then added to the upper well. SDF-1α (50 ng/ml) was added to the bottom chamber.
Assay of cytokine secretion
Cytokine secretion was examined as described previously (29) . The cells were preincubated for 2 h with the indicated concentrations of CSPG-DS before their stimulation with immobilized anti-CD3 mAb.
Western blot analysis of T cell nuclear extracts
Purified human T cells (5×10 6 ) were preincubated for 2 h with different concentrations of CSPG-DS. The cells were then replated at the same CSPG-DS concentrations on 24-well plates precoated for 24 h with anti-CD3 mAb. The T cells were lysed in 10 mM HEPES, 1.5 mM MgCl 2 , 1 mM dithiothreitol, 1 mM PMSF, and 0.5% Nonidet P-40 (buffer A). The lysates were incubated on ice for 10 min and then centrifuged at 2000 rpm for 10 min at 4°C. The supernatants (cytoplasmic extracts) were set aside and the pellets (nuclei) were suspended in buffer containing 30 mM HEPES, 450 mM NaCl, 25% glycerol, 0.5 mM EDTA, 6 mM dithiothreitol, 12 mM MgCl 2 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml pepstatin, and 1% phosphatase inhibitor cocktail (buffer B), and the suspension was incubated on ice for 30 min. The lysates were cleared by centrifugation (30 min, 14×10 3 rpm, 4°C), and the resulting supernatants were analyzed for protein content. Sample buffer was added, the mixture was boiled, and aliquots of samples containing equal amounts of protein were separated on a 10% SDS−PAGE gel and transferred to nitrocellulose membranes. The membranes were blocked with TBST buffer containing 5% of low-fat milk, 20 mM Tris pH 7.5, 135 mM NaCl, and 0.1% Tween-20, and probed with the following mAbs, all diluted 1:1000 in the same buffer: anti-NF-κB, antisuppressors of cytokine signaling protein (SOCS-3), and anti-lamin B (control). Antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). Immunoreactive protein bands were visualized using labeled secondary antibodies and the enhanced chemiluminescence system. For assay of SOCS-3, the cells were incubated for 3 h with CSPG-DS and lysed with buffer B without separating the nuclei from the cytoplasm, and the procedure was completed as described above.
RNA purification, RT−PCR, and cDNA synthesis
After pretreatment with the indicated concentrations of CSPG-DS for 2 h, human T cells were replated for 6 h on 24-well plates precoated with anti-CD3 mAb. They were then lysed with TRI reagent (MRC, Cincinnati, OH), and total cellular RNA was purified from the lysates using the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA was reverse-transcribed to cDNA using SuperScript II (Promega, Madison, WI), as recommended by the manufacturer. We assayed the expression of specific mRNAs by RT−PCR, using the messageScreen™ Human Th1/Th2 Cytokine Set 1 Multiplex PCR® kit (BioSource International, Camarillo, CA), according to the manufacturer's instructions.
T cell apoptosis
Human T cells (2×10 6 cells/ml) were incubated for 2 h with the indicated concentrations of CSPG-DS in RPMI medium containing 10% FCS and then plated on 24-well plates (nontissueculture grade) precoated with anti-CD3 mAb (1 μg/ml; overnight) and cultured for 72 h. The percentage of cells undergoing apoptosis was determined using the annexin V-detection assay (Bender MedSystem, San Bruno, CA). The cells were incubated for 10 min in the dark at room temperature in 200 μl of buffer containing FITC-conjugated human annexin V (Bender MedSystem). Propidium iodide (10 μl) was added to each sample, and the percentage of cells undergoing apoptosis was analyzed by FACS® at 525 nm using CELLQuest Software. Cells that stained for annexin V and did not take up propidium iodide were identified as apoptotic cells.
Statistical analysis
Statistical analysis was performed using the Student's t test.
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RESULTS
CSPG-DS alleviates clinical symptoms of EAE in mice
In an attempt to determine whether CSPG-DS can affect the course of CNS autoimmune diseases, we first used the mouse model of EAE, an autoimmune inflammatory disease adopted as a model for multiple sclerosis (MS) (31) . In susceptible mouse strains, EAE can be induced by active immunization with CNS proteins or peptides derived from them, such as myelin basic protein, proteolipid protein, or myelin oligodendrocyte glycoprotein (MOG), all emulsified in adjuvant. It can also be induced by the passive transfer of T cells reactive to these CNS antigens (31) . In both MS and EAE, T helper (Th)-1 cells are present in the CNS in abundance at the peak of the disease. A number of studies indicate that the pathogenesis of EAE is mediated by uncontrolled myelin-specific Th1 cells that secrete excessive levels of IFN-γ, TNF-α, and interleukin (IL)-2 (32-35).
In the present study, we induced EAE in four groups of mice. To examine the effect of CSPG-DS on the clinical symptoms of the disease, three of the groups were injected intravenously with CSPG-DS, according to different regimens: mice in the first group were treated only on day 0, mice in the second group on day 0 and day 7, and mice in the third group on days 0, 3, 5, and 7. Mice in the fourth group (control) were injected with PBS. Figure 1A shows a dose-dependent decline in severity of the induced disease with increasing numbers of CSPG-DS injections. The repeated treatment with CSPG-DS in mice of the third group significantly attenuated the symptoms of the disease and shortened its duration. CSPG-DS treatment also delayed disease onset, as shown in Fig. 1B .
CSPG-DS protects retinal ganglion cells from EAU
To investigate the ability of CSPG-DS to attenuate neuronal consequences of inflammationinduced insults (36), we used a second animal model of inflammation-mediated neuropathology, namely, the rat model of EAU (37) . Inflammation in this model is associated with the loss of retinal ganglion cells (RGCs) (38) and can be accurately quantified (39) . Treatment with steroids was shown to alleviate the inflammatory symptoms of EAU; however, it causes an increase in neuronal death (25, 28) . In the present study, EAU was induced in Lewis rats by active immunization with R16, a pathogenic peptide derived from interphotoreceptor retinoid binding protein (IRBP) (40). Three groups of immunized rats (EAU induced) were included in the experiment. One group was injected intravenously with the steroid drug MP, the second group received an intravenous injection of CSPG-DS, and the third group was treated with PBS only. The regimen for steroid treatment was adopted from protocols previously used to treat rats with EAU (28) . We counted the surviving RGCs in each group 12 days after the immunization. Immunization of naïve Lewis rats with R16 emulsified in CFA was found to cause RGC loss of 52 ± 2% (mean±SD) relative to normal rats. Treatment of R16-immunized rats with MP not only was not beneficial for neuronal survival, but also [in agreement with previous studies (28)] caused further RGC loss (59±1.6%; mean±SD). In contrast, treatment of the R16-immunized rats with CSPG-DS reduced the RGC loss to only 24 ± 9% ( Fig. 2A) .
To better understand the mechanism through which CSPG-DS exerts its beneficial effect on neuronal survival in this model of inflammation-induced neuropathology, we used immunohistochemistry to compare the numbers of T cells in the eyes of rats with EAU treated by CSPG-DS, MP, and PBS (control). We examined the uvea and the iris, both characterized by marked infiltration of T cells when the inflammatory disease is at its peak (41) . The numbers of T cells in the examined sites of eyes with EAU were reduced significantly by treatment with CSPG-DS, and even more significantly by treatment with the steroid (Fig. 2B-C) .
Local inflammation in the CNS is often an outcome of T cell infiltration and the activation of microglia/macrophages, both of which play a role in pathological process, as well as in repair, depending on their phenotypes and on the timing and intensity of their activation. We therefore examined how the different treatments affect the microglial or macrophage response (because no phenotypic difference exists to distinguish between resident activated microglia and infiltrating macrophages, we refer to these cell types together as microglia/macrophages when describing our immunohistochemical data). Both activated microglia and macrophages can be identified by labeling for IB-4 lectin. As previously reported by our group, CSPG-DS can affect the activation of microglia by inducing them to adopt a phenotype, which is protective of neural tissue (17) . Microglia activated by CSPG-DS can protect neural tissue from death in an ex vivo model of organotypic hippocampal slice cultures (OHSCs) (17) , in which cell death is a consequence of tissue excitation and therefore simulates mechanical insult. CSPG-DS-activated microglia express class II major histocompatibility complex proteins (MHC-II) (17) . Microglia that can support neuronal survival were recently shown to express MHC-II (42, 43) . In the present study MHC-II expression is used as a marker of CSPG-DS-induced activation. We therefore examined, in rats immunized with R16 that were treated with CSPG-DS, MP, or PBS, the specific effect of each treatment on the numbers of microglia/macrophages and the incidence among them of MHC-II-expressing cells. Immunohistochemical staining for IB-4 indicated that there was no significant difference in the numbers of microglia/macrophages among the different treatments. Yet, cells expressing both MHC-II and IB-4 were most abundant in CSPG-DS-treated group, whereas they almost disappeared in treatment with the steroid (Fig. 2D-E ).
To summarize, our results indicate that CSPG-DS reduced the numbers of T cells but induced MHC-II expression in microglia/macrophages, whereas MP reduced the numbers of T cells and the expression of MHC-II on microglia/macrophages. It thus appears that steroid treatment inhibited the local immune response, whereas CSPG-DS modulated it.
CSPG-DS attenuates the delayed-type hypersensitivity (DTH) response in mice
The above results indicate that CSPG-DS reduced the numbers of T cells in the eyes of rats with EAU. To further examine the effect of CSPG-DS on T cells, we used the DTH model, which is usually applied to analyze the effects of a specific compound on T cell migration or activation. Activation of T cells and their recruitment into an area of inflammation are crucial steps in development of the DTH response. Figure 3 shows that the DTH response in mice treated with CSPG-DS was significantly weaker than in untreated mice (~40% reduction in DTH response at the most effective concentration of 1 μg/mouse), indicating that CSPG-DS can control T cellassociated inflammatory responses.
CSPG-DS down-regulates T cell motility
Attenuation of the DTH response may usually be attributed either to the decreased presence of T cells in an irritated region (a manifestation of reduced T cell migration) and/or a decline in their activity (a manifestation of reduced cytokine secretion). To determine whether the effect of CSPG-DS is mediated via a direct effect on T cell motility, we assessed the migration of T cells toward the chemoattractive agent, stromal cell-derived factor-1 (SDF-1α), in a transwell migration apparatus. SDF-1α is an effective chemoattractant for CNS-derived T cells (44) and is associated with several immunopathological CNS insults (45, 46) . We found that T cells treated for 2 h with CSPG-DS showed reduced migration toward SDF-1α in the transwell migration apparatus relative to that of untreated cells (24±12% migration relative to control at 1 µg/ml of CSPG-DS) (Fig. 4A) .
A prerequisite for T cell migration is the adhesion of T cells to a matrix or to target cells (47) . Such adhesion typically arrests the normal flow of T cells within a blood vessel, enabling them to migrate through the vessel wall to an extravascular inflammatory site. In an attempt to understand how CSPG-DS reduces T cell migration, we examined its effect on T cell adhesion after the activation of T cells by SDF-1α (48) (49) (50) (51) (52) . Adhesion of T cells that were pretreated with CSPG-DS for 2 h before their exposure to SDF-1α was significantly reduced relative to that of T cells that were treated with SDF-1α alone (34±3% migration relative to control at 1 µg/ml of CSPG-DS) (Fig. 4B ). In these in vitro assays, CSPG-DS at a concentration of 10 ng/ml reached almost the maximal level of activity; further increase of the CSPG-DS concentration showed an activity, which was only slightly higher.
T cell growth, differentiation, and chemotactic responses require coordinated action between cytokines or chemokines and their intracellular targets. We were therefore interested in determining whether CSPG-DS can also affect an intracellular mechanism known to be associated with an attenuated response to chemokines. Members of the SOCS-3 family of proteins have been identified as feedback regulators of JAK/STAT activation, through their binding to JAK kinases or cytokine receptors (53) . Therefore, by down-regulating the chemokine-mediated activation signal, these proteins reduce cell migration in several different contexts, both in vivo and in vitro (54) . SOCS-3 specifically down-regulates signals associated with responses mediated through the SDF-1α receptor, CXCR4 (54) . We examined by Western blot analysis the levels of SOCS-3 in T cells after pretreatment with CSPG-DS for 2 h, and subsequent activation with anti-CD3 antibodies (commonly used for T cell activation). CSPG-DS treatment resulted in an increase (5.9-fold at 100 ng/ml of CSPG-DS) in SOCS-3 expression relative to untreated T cells (Fig. 4C) , suggesting that CSPG-DS suppresses the signaling pathway through which SDF-1α mediates its effects, and establishing a possible mechanism for the reduction in T cell motility.
CSPG-DS reduces secretion of cytokines by activated T cells
A decrease in secretion of the Th1-associated cytokines IFN-γ, TNF-α, or both can also contribute to the observed weakening of the DTH response (55). We therefore examined by ELISA the direct effects of CSPG-DS on the secretion of these cytokines by T cells. Pretreatment of T cells for 2 h with CSPG-DS before their activation with anti-CD3 antibodies caused a significant reduction in their secretion of IFN-γ (~2.2 fold at 1 µg/ml of CSPG-DS) (Fig. 5A ) and TNF-α (~2.8 fold at 1 µg/ml of CSPG-DS) (Fig. 5B) relative to T cells that were not treated with CSPG-DS.
The NF-κB cascade is an important pathway in cytokine production. The activity of NF-κB is governed by its translocation to the nucleus, where it controls the transcription of genes responsible for regulating cell proliferation, cell survival, and inflammation (56) . We examined the ability of CSPG-DS to regulate NF-κB activity induced as a result of T cell receptor (TCR) activation by anti-CD3 antibodies. Figure 5C shows a Western blot analysis of NF-κB levels. A reduction in NF-κB expression in activated T cells in response to CSPG-DS, supporting the possibility that the NF-κB pathway is a mechanism through which CSPG-DS reduces T cell activation and down-regulates the secretion of IFN-γ and TNF-α.
A number of factors shown to down-regulate the secretion of Th1-associated cytokines can also induce a phenotypic switch in the cytokine-secretion profile of activated T cells. Attenuation of EAE is often correlated with increased secretion of the cytokines IL-4 and IL-13, both associated with the T-helper (Th)2-cell phenotype (57) . A phenotype switch usually results in a significant change in the message levels to the relevant cytokines and therefore can be easily detected using semiquantitative RT-PCR method. To determine whether the observed CSPG-DS-mediated down-regulation of IFN-γ and TNF-α is linked to an increase in Th2-associated cytokines, we analyzed the mRNA levels of IL-4 and IL-13 in T cells that were pretreated with CSPG-DS for 2 h, washed, and then activated by incubation with anti-CD3 antibody. Figure 5D shows the mRNA levels of each cytokine examined. Th2-associated cytokines message levels were not affected by treatment with CSPG-DS, indicating that the mechanism whereby CSPG-DS modulates T cell activity is not via a cytokine switch.
To exclude the possibility that the observed down-regulation of T cell activation and migration after treatment with CSPG-DS was the result of selective cell death rather than a result of the change in T cell activation, we examined the effect of CSPG-DS on T cell apoptosis. T cells were activated with anti-CD3 antibody, and the percentage of cells undergoing apoptosis was determined using the annexin V-detection assay. Treatment with CSPG-DS (10 ng/ml to 1 µg/ml) did not affect viability of the activated T cells and caused an insignificant increase in cell death (maximal increase of only 2.8±3.8%).
DISCUSSION
The results of this study show that CSPG-DS, an enzymatic degradation product of CSPG, alleviates the clinical symptoms associated with EAE and protects against neuronal loss associated with the inflammatory conditions in EAU. In addition to rescue of neurons, the beneficial effect of CSPG-DS in EAU was manifested by a decrease in the number of accumulated T cells and promotion of a beneficial mode of microglial/macrophage activation. Attenuation of the T cell response was shown by the down-regulation of a DTH response in vivo and the reduction in T cell motility and cytokine secretion in vitro.
CSPG-DS is a 6-sulfated disaccharidic breakdown product of the extracellular molecule, CSPG, generated after its ex vivo degradation using ChABC (58) . CSPG represents a diverse class of complex macromolecules that share a general molecular structure, comprising a central core protein with a number of covalently attached carbohydrate chains, the glycosaminoglycans Page 9 of 24 (page number not for citation purposes) (GAGs). Each GAG is made up of repeating disaccharide (DS) units (glucuronic acid/iduronic acid-N-acetylgalactosamine), which are either not sulfated or possess one sulfate per DS (59) . The composition of the GAG chains in the CNS varies during development. The 4-sulfated CSPG is most abundantly expressed in the developing CNS (60, 61) . In the adult animal, 6-sulfated GAG is up-regulated after CNS injury (62) . A number of groups have demonstrated that CSPG is a major inhibitor of axonal outgrowth (recently reviewed (11)), and it is known to induce activation of an inflammatory response (14) . Therefore, accelerating its degradation has been proposed as a potential treatment approach for CNS injuries (11, 12, 15) .
In a previous study by our group (17), CSPG-DS was found to be a highly potent compound that protects neurons against toxicity both in vivo and in vitro, while also activating microglia to adopt a phenotype that is protective of neural tissue and is associated with significant expression of MHC-II proteins. These results have led us to suggest CSPG-DS as a potential agent for modulation of the local immune response, in general, and for the treatment of pathological CNS conditions, in particular.
In the present study, we tested this hypothesis using rodent models of EAE and EAU. In both of these models, the damage is mediated by the presence of excessive levels of activated T cells in the injured CNS (32, 63) and thus, by uncontrolled levels of local activation of microglia/macrophages (19, 20, (64) (65) (66) (67) . Indeed, unbalanced immune activation in the context of the CNS, irrespective of the primary trigger (injury, phagocytic attack), can result in tissue damage, as is observed in autoimmune neuropathologies such as EAE or EAU. However, balanced immune activation holds a curative potential. Damaged neural tissue can benefit from the healing potential of microglia/macrophages (68) , and even from T cells (69, 70) under the proper set of activation conditions. Actually, the same myelin-directed T cells, which are destructive in EAE (where they are present in excessive levels), can promote recovery following spinal cord injury (69, 70) or induce remyelination (27) , provided that their levels and the cytokines they produce are well controlled. Yet, inflammation-associated pathologies are often treated using steroids (22) (23) (24) . Previous studies in our laboratory, at least in the context of EAU, have demonstrated that steroid treatment may result in additional neuron death (28) , possibly because such global immune suppression does not provide the potential benefit of controlled immune activation. Indeed, recent studies have demonstrated adverse effects of steroid treatment in neurodegenerative disorders (25, (71) (72) (73) .
In the present study, we showed that CSPG-DS, unlike treatment with the steroid, MP, resulted in a significant increase in the number of surviving RGCs after EAU induction. Immunohistochemical analysis of the outcome of treatment with MP and with CSPG-DS showed that whereas steroid treatment significantly reduced both T cell accumulation and microglial/macrophage activation in the treated eyes, treatment with CSPG-DS led to a more moderate reduction in T cell accumulation, along with activation of the microglial/macrophage response. In agreement with our previous studies, this activation of microglia was not unexpected (17) . CSPG-DS is a potent activator of microglia, and causes them to adopt a protective phenotype capable of promoting neural tissue survival in the ex vivo organotypic hippocampal slice culture (OHSC) model (17) . Such microglial activation is also associated with an increased expression of MHC-II, with no detectable increase in production of the major neurotoxic factors, TNF-α and nitric oxide (NO), commonly associated with microglial toxicity (74, 75) . These effects on microglia are mediated via the direct activation of ERK1/2 and PYK2, two major signaling cascades in microglial activation pathways (17) . The fate of activated microglia is dependent on the stimulation they receive. A correlation was observed between the ability of microglia to express MHC-II and their capacity to protect neural tissue (42) . Microglia acquire a highly toxic phenotype and significant reduction in MHC-II expression when activated by LPS (74) (75) (76) , whereas their stimulation by controlled levels of IFN-γ or IL-4 induces them to adopt a neuroprotective phenotype and to express high levels of MHC-II (42, 43) . Not all MHC-II expressing microglia are protective; microglia activated overwhelmingly high levels of IFN-γ, although they express MHC-II, might loose their beneficial phenotype due to TNF-α production (42, 77) . It is intriguing that a molecule like MHC-II, which is associated with T cell activation, is expressed under both pathological and protective conditions. However, it seems that the crucial parameter is the balanced regulation of T cell levels and the extent of their activation, as well as the other features of the activated microglia in addition to MHC-II. MHC-II expression is only a single parameter in the pathogenesis of T cell mediated disorders. It is also possible that expression of MHC-II is not functionally correlated with a protective role, but circumstantially, that a common intracellular pathway may lead to MHC-II expression and activation of other features needed for tissue protection. This might explain the fact that CSPG-DS-activated microglia maintain their protective phenotype in the absence of T cells (17) .
Concomitantly with its effect on microglia, CSPG-DS also reduced the accumulation of T cells at the inflammation site. Excessive emigration of T cells into the CNS is a crucial stage in the induction of immunity-induced neuropathologies. In the present study, we demonstrated that CSPG-DS directly affects T cells motility and activation. CSPG-DS administration resulted in significant attenuation of DTH response, an in vivo manifestation of cell-mediated immune response, which provides protection against intracellular pathogens. The direct effect of CSPG-DS on down-regulation of T cell motility was manifested here by a reduction of T cell adhesion and migration in vitro. In addition, CSPG-DS down-regulated secretion of the Th1-associated cytokines IFN-γ and TNF-α, but did not induce a switch in the T cell phenotype to production of Th2-associated cytokines. This observation is in line with the recently reported finding that therapy of MS does not appear to require a T cell phenotype switch (78) and is also supported by reports that IFN-γ and even TNF-α at low levels might be beneficial for neuronal tissue (69, (79) (80) (81) . The observed reduction in IFN-γ and TNF-α production by T cells can be attributed, at least in part, to the CSPG-DS-induced decrease in the nuclear transcription factor, NF-κB. NF-κB plays a crucial role in the regulation of immunity and inflammation, stimulating the transcription of many cytokine-associated genes, including TNF-α and IFN-γ (82) . The levels of SOCS-3 in T cells were also significantly increased after incubation with CSPG-DS. This might represent another possible mechanism underlying the effects of CSPG-DS on T cell motility, because SOCS-3 has been associated with an attenuated response to chemokines and reduced cell migration both in vivo and in vitro (54) . Our data further indicate that the observed changes in T cell activity upon CSPG-DS application cannot be attributed to increased cell death, because the effect of the disaccharide on T cell apoptosis was not significant. In addition, the possible contribution to the observed neuroprotection of a direct interaction between CSPG-DS and the affected/damaged neurons cannot be ruled out, as our previous studies have demonstrated (17) .
The specific receptor for CSPG-DS has not yet been determined. It is possible that CSPG-DS interacts with CSPG receptors either as agonist or as an antagonist. Several receptors were suggested to interact with different members of the CSPG family, for example, CD44 with aggrecan (83) and TLR-2 and TLR-4 with biglycan (84) . It is unlikely, however, that CSPG-DS acts as CSPG antagonist since its in vitro effects could be observed in the absence of CSPG. Yet, the occurrence of such a mechanism in vivo cannot be ruled out. The effects of CSPG-DS, appear to be highly specific, as there is a significant difference in the level of activity between the sulfated and nonsulfated disaccharides derived from CSPG (17) .
It thus appears that CSPG-DS, which is derived from a matrix molecule observed in various pathological conditions in the CNS, and known for its growth inhibitory effect, as well as its proinflammatory potential, can modulate the immune response. Although the effect of CSPG-DS in the examined models is mostly preventive of neural loss, unpublished data from our group indicate that in a model of chronic elevation of intraocular pressure, application of CSPG-DS on day 14 after disease induction, resulted in a beneficial effect on neuronal loss. Even though this does not provide clear proof for to the ability of this compound to reverse tissue damage, it may indicate the potential of such a mechanism and requires further investigation.
CSPG-DS seems to be of cross-species nature, as manifested by the effects of CSPG-DS on human T cells in vitro, substantiated by the DTH-response in mice and by T cell immunohistochemical analysis in EAU in rats. The experimental paradigms used in the present study were directed to reveal different aspects of CSPG-DS's mechanism of action. CSPG-DS has multicellular targets, and the EAE and DTH models in mice were used to examine its effects on T cell activation. The EAU model in rats was applied to examine neuronal survival and CSPG-DS effects on both T cells and microglia. Moreover, the effects that were observed across the different species were also consistent within each species; in mice, for example, CSPG-DS attenuates T cell responses in DTH response and EAE, and it further induced MHC-II expression in microglia in mice brains (data not shown). It therefore seems that the effects of CSPG-DS on recovery were mediated in both species via the same cellular components attenuating T cell response and altering microglia activation.
Although the endogenous occurrence of this disaccharide requires further investigation, this study supports the therapeutic potential of this compound. Our study indicates that CSPG-DS represents a novel immunomodulator, which is distinct from other known steroidal or nonsteroidal immunomodulating compounds. CSPG-DS exerts dual and apparently opposite effects on T cells and microglia; it reduces T cell activation without imposing a phenotype switch and induces a local beneficial activation of microglia/macrophages. The two effects are complementary in leading to a local protective immune environment that is needed for tissue repair and restoration. 
